Ignite Creation Date:
2024-05-05 @ 6:34 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00502112
Status:
COMPLETED
Last Update Posted:
2011-10-12
First Post:
2007-07-13
Brief Title:
A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes MDS
Sponsor:
Seagen Inc
Organization:
Seagen Inc
Organization Data
Organization:
Seagen Inc
Class:
INDUSTRY
Study ID:
SG033-0002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Seagen Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None